Evidence map›Paper›PMID 34597140›Full record

ArticleScience advances2021

GABARAP sequesters the FLCN-FNIP tumor suppressor complex to couple autophagy with lysosomal biogenesis.

Jonathan M Goodwin, Ward G Walkup, Kirsty Hooper, Taoyingnan Li, Chieko Kishi-Itakura, Aylwin Ng, Timothy Lehmberg, Archana Jha, Sravya Kommineni, Katherine Fletcher and 16 more

Abstract read
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. mBio · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. ATG16L1 controls mammalian vacuolar proton ATPase.The Journal of cell biology · 2025
    Article
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Jonathan M GoodwinCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.ORCID 0000-0003-1593-5098
Ward G WalkupCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.ORCID 0000-0002-0385-6256
Kirsty HooperSignalling Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0003-2900-3849
Taoyingnan LiDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0003-0548-9442
Chieko Kishi-ItakuraImaging Facility, Babraham Institute, Cambridge, UK.
Aylwin NgCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.
Timothy LehmbergCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.ORCID 0000-0002-3259-8014
Archana JhaCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.
Sravya KommineniCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.
Katherine FletcherSignalling Programme, Babraham Institute, Cambridge, UK.
Jorge Garcia-FortanetCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.
Yaya FanViva Biotech, Shanghai, China.
Qing TangViva Biotech, Shanghai, China.
Menghao WeiViva Biotech, Shanghai, China.
Asmita AgrawalSai Life Sciences Limited, Pune 411057, Maharashtra, India.
Sagar R BudheSai Life Sciences Limited, Pune 411057, Maharashtra, India.
Sreekanth R RouduriSai Life Sciences Limited, Pune 411057, Maharashtra, India.
Dan BairdCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.ORCID 0000-0002-2748-3212
Jeff SaundersCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.ORCID 0000-0003-2303-3406
Janna KiselarNEO Proteomics Inc., Cleveland, OH 44106, USA.ORCID 0000-0002-6240-7522
Mark R ChanceNEO Proteomics Inc., Cleveland, OH 44106, USA.ORCID 0000-0002-2991-6405
Andrea BallabioTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.ORCID 0000-0003-1381-4604
Brent A AppletonCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.
John H BrumellDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0002-5802-7789
Oliver FloreySignalling Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0002-1075-7424
Leon O MurphyCasma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Funding

Orbitrap Fusion Lumos Tribrid Mass SpectrometerS10OD026882 · OD · CASE WESTERN RESERVE UNIVERSITY · PI CHANCE, MARK R · 2019 to 2019
$1.0M
Cancer Research UK 16337NIH HHS S10 OD026882
6 · The paper itself

Abstract

Adaptive changes in lysosomal capacity are driven by the transcription factors TFEB and TFE3 in response to increased autophagic flux and endolysosomal stress, yet the molecular details of their activation are unclear. LC3 and GABARAP members of the ATG8 protein family are required for selective autophagy and sensing perturbation within the endolysosomal system. Here, we show that during the conjugation of ATG8 to single membranes (CASM), Parkin-dependent mitophagy, and

Identifiers

PMID34597140
PMCPMC10938568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.